Palvella Therapeutics, Inc. (PVLA) Earnings

Management highlights

- Lead Program (Cuturin Rapamycin for Microcystic Lymphatic Malformations): • Achieved three key Q2 2026 milestones: positive Phase 3 SELVA study results, completed in-person pre-NDA meeting with the FDA, and submission of the first NDA module, with FDA granting rolling review under the program's Breakthrough and Fast Track designations. • The SELVA study met all primary and secondary endpoints with high statistical significance, with 95% of patients demonstrating improvement at Week 24; a new pediatric subgroup analysis (ages 6-11) showed 100% of patients improved, with all patients electing to continue treatment in the open-label extension. • Pre-launch commercial preparation is well underway: the core commercial and medical affairs leadership team is fully assembled, the planned sales force size has been increased to 40 reps (upper end of prior guidance), over 200 of 400 target clinics have already been engaged, and internal patient services and access infrastructure is being built. • Payer research confirms strong support for orphan pricing in the $100,000-$200,000 per patient per year range, with favorable reimbursement outlook. - Pipeline Expansion: • Cuturin Rapamycin for Cutaneous Venous Malformations (CVM): Positive Phase 2 TOIVA results showed 73% of patients improved, with benefits continuing through Week 24; an end-of-Phase 2 meeting with the FDA is planned for Q4 2026, with Phase 3 initiation on track for Q4 2026, and potential approval targeted for 2029. • Cuturin Rapamycin for Clinically Significant Angiocaritomas: First patient dosing was completed in Q2 2026 (ahead of schedule), and Phase 2 data is expected in H2 2027, with potential approval targeted for 2031 via a supplemental NDA pathway. • Cuturin Pitavastatin for Disseminated Superficial Actinic Porokeratosis (DSAP): Phase 2 initiation remains on track for Q4 2026, with strong inbound patient interest already recorded. • A fourth Cuturin platform indication will be announced later in 2026, with additional pipeline opportunities in active planning. - Strategy: • The company focuses exclusively on rare skin and vascular diseases with no existing FDA-approved therapies, leveraging the shared Cuturin localized delivery platform to address shared causal biological pathways. Across all four lead indications, more than 80% of surveyed physicians stated they would use the approved Cuturin product as first-line therapy if available. The company estimates the combined U.S. addressable patient population will exceed 300,000 across all approved indications.

Guidance

- NDA submission for Cuturin Rapamycin (microcystic lymphatic malformations) remains on track to be completed in H2 2026, with potential FDA approval targeted for H1 2027. - Phase 3 initiation for Cuturin Rapamycin (cutaneous venous malformations) remains on track for Q4 2026, with potential approval targeted for 2029. - Phase 2 initiation for Cuturin Pitavastatin (DSAP) remains on track for Q4 2026. - Data from the Phase 2 Cuturin Rapamycin (clinically significant angiocaritomas) trial is expected in H2 2027, with potential approval targeted for 2031. - A fourth new Cuturin platform indication will be announced by the end of 2026. - 2026 full-year cash operating expenditure guidance is set at $85 million to $95 million, a modest upward revision from prior plans to accommodate expanded commercial launch preparation and pipeline investment. The company remains well-capitalized through approval and a standalone commercial launch. - Platform designation for the Cuturin platform will be pursued with the FDA after the first approval for Cuturin Rapamycin, to expedite review of future pipeline candidates.

Segment performance

Povella Therapeutics is a clinical-stage biotech company focused exclusively on rare disease therapies, with no commercial revenue generated to date. As of June 30, 2026, the company held $251 million in cash on its balance sheet, resulting from an oversubscribed $230 million capital raise completed in February 2026, exceeding its original $150 million target. 2026 full-year cash operating expenditure guidance is set at $85 million to $95 million, a modest increase from prior plans to accommodate expanded commercial and pipeline investments. All product development programs are currently in clinical stages, so no revenue or revenue contribution percentage is reported for any segment.

Risks & headwinds

- The FDA did not grant Breakthrough Therapy Designation for cutaneous venous malformations based on the initial 12-week data package, though the development path remains unchanged, and the company plans to resubmit with full 24-week data and additional patient experience data following the end-of-Phase 2 meeting. • All product candidates are still in clinical development, and there is no guarantee of regulatory approval, successful commercial launch, or payer reimbursement even if approval is obtained. • Clinical trial enrollment and results may differ from expectations, which could delay development timelines or alter trial design requirements. • Pre-launch commercial and medical operations investments increase near-term cash expenditure, and launch adoption may not meet management expectations.

Analyst Q&A

• Q: Can you confirm that your estimate of greater than 30,000 diagnosed U.S. MLM patients is still accurate, and how are you approaching patient identification ahead of launch? /

  A: Management confirms the estimate is conservative and remains accurate; real-world claims data points to a total of 45,000 to 95,000 diagnosed patients. Patient identification efforts are focused on engaging high-volume vascular anomaly centers where most MLM patients are concentrated, with field reps and strong presence at medical congresses to reach treating physicians.

• Q: What is the target enrollment for the DSAP Phase 2 study, and could it read out earlier than the angiocaritoma program? /

  A: DSAP Phase 2 is planned to enroll approximately 15 patients. The angiocaritoma Phase 2 started ahead of schedule in H1 2026 and is still set to read out in H2 2027. Final timelines for DSAP readout will be confirmed when Phase 2 initiates in H2 2026.

• Q: How is the 40-person sales force planned across vascular anomaly clinics, and what is your hub and reimbursement support strategy? /

  A: The market is split into three tiers: 400 high-volume centers (tier 1) that manage ~15,000 MLM patients, half of which are dedicated vascular anomaly centers. All tiers will get personal sales rep promotion, plus digital marketing and an inside sales team to expand reach. The patient services and reimbursement hub team is being sized at the high end of the initial range; management expects rare disease prior authorization requirements, which the team will be set up to navigate, and does not expect payers to require step therapy through unapproved treatments if Cuturin Rapamycin is approved.

• Q: Have you sized the CVM market, will you pursue orphan designation for CVM, and is OLE data required for the MLM NDA filing? /

  A: External publications estimate 135,000 U.S. CVM patients, so Povella uses a conservative estimate of greater than 75,000 diagnosed patients publicly. The company intends to pursue orphan designation for CVM. OLE data from the SELVA study will be submitted as a safety update to the FDA after the initial NDA filing is complete, and new data cuts from the extension will be presented at future medical congresses.

• Q: Does the lack of initial Breakthrough designation for CVM change your approach to the upcoming end-of-Phase 2 meeting with the FDA? /

  A: Management states the absence of initial Breakthrough designation does not change their approach. They will present full 24-week Phase 2 data and new patient qualitative experience data at the meeting, and will work collaboratively with FDA to align on the appropriate Phase 3 design to bring the therapy to patients as quickly as possible. Povella already holds Fast Track designation for CVM.